COMMUNIQUÉS West-GlobeNewswire

Zomedica’s Dr. Bonnie Bragdon to Speak at AVMA Convention 2019 on Sunday, August 4
25/07/2019
ANN ARBOR, Mich., July 25, 2019 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V: ZOM), a veterinary diagnostic and pharmaceutical company, today announced Dr. Bonnie Bragdon, Vice [...]
LHC Group Announces Second Quarter 2019 Earnings Release and Conference Call Dates
25/07/2019
LAFAYETTE, La., July 25, 2019 (GLOBE NEWSWIRE) -- LHC Group, Inc . (NASDAQ: LHCG) today announced details for the release of its results for the second quarter and six months ended June 30, 2019. LHC Group plans to [...]
Medcolcanna Signs Letter of Intent with Top Medical Center and Completes Purchase of Innovative CBD Products
25/07/2019
BOGOTÁ, Colombia, July 25, 2019 (GLOBE NEWSWIRE) -- Medcolcanna Organics Inc . (TSX-V: MCCN) (“ Medcolcanna ” or the “ Company ”), a Canadian medical cannabis company with operations in Colombia, is pleased to announce [...]
BioCardia Signs Exclusive Development Agreement With AstraZeneca
25/07/2019
BioCardia to Receive Sizable Upfront Payment SAN CARLOS, Calif., July 25, 2019 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative [...]
Sol-Gel Technologies Hosting Analyst & Investor Day
25/07/2019
Notice of allowance for U.S. patent application extends TWIN patent protection to 2038 Clinical study for SGT-210 in palmoplantar keratoderma (PPK) intended to begin in early 2020 Webcast of Analyst & Investor Day [...]
Auxly Welcomes $123 Million Investment and R&D Partnership with Imperial Brands
25/07/2019
Driving future growth in derivative cannabis products Imperial Brands to invest approximately $123 million by way of a debenture convertible into 19.9% ownership of Auxly at a conversion price of $0.81 per share Auxly [...]
ORYZON Raises Its Share Capital by EUR 20 Million Through a Private Placement
25/07/2019
MADRID, Spain, July 25, 2019 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (MAD: ORY) (" Oryzon " or the " Company "), a clinical‐stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with [...]
Curetis to Present at Solebury Trout European Biotech Investor Day in NYC
25/07/2019
Amsterdam, the Netherlands, San Diego, CA, USA, and Holzgerlingen, Germany, July 25, 2019, 08:00 am CEST - Curetis N.V. (the " Company " and, together with Curetis USA Inc. and Curetis GmbH, " Curetis "), a developer of [...]
2019 half-year financial report
25/07/2019
Press release 25 July 2019 Embargo till 08:00h CET FINANCIERE DE TUBIZE SA Allée de la Recherche 60, 1070 Brussels Contact: Anne Sophie Pijcke, day-to-day management, aspijcke@icloud.com 2019 half-year financial report [...]
Rapport financier semestriel 2019
25/07/2019
Communiqué de presse 25 juillet 2019 Embargo jusqu’à 08:00h CET FINANCIERE DE TUBIZE SA Allée de la Recherche 60, 1070 Bruxelles Contact: Anne Sophie Pijcke, directeur, aspijcke@icloud.com Rapport financier semestriel [...]
Ossur Hf : Interim report Q2 2019
25/07/2019
Announcement no. 44/2019 Interim report Q2 2019 25 July 2019 Highlights Sales growth of 18% in local currency in Q2 2019 and organic sales growth of 7%. Sales growth of 19% in local currency in 1H 2019 and organic sales [...]
Genkyotex Announces Positive Post-Hoc Analysis of PBC Phase 2 Trial and Reports Cash Position at June 30, 2019
25/07/2019
Setanaxib (GKT831) achieved statistical significance (p=0.02) for primary endpoint with the 400mg BID versus placebo, after correction of non-normal distribution (outliers) in 400mg OD In advanced patients, setanaxib [...]
Genkyotex Annonce Les Résultats Favorables de L’analyse Post-Hoc de L’essai de Phase 2 Dans la CBP et Publie sa Situation de Trésorerie au 30 Juin 2019
25/07/2019
Le setanaxib (GKT831) atteint la signification statistique (p=0,02) pour le critère d’efficacité principal à 400mg BID contre placébo, après correction des aberrations de distribution à 400mg OD Chez les patients à un [...]
argenx to report half year 2019 financial results and second quarter business update on August 1, 2019
25/07/2019
July 25, 2019 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the [...]
Number of shares and voting rights of Innate Pharma as at July 17, 2019
25/07/2019
NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS AT JULY 17, 2019 Marseille, France, July 25, 2018, 7:00 AM CET Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of the [...]
Nouveau nombre d’actions et de droits de vote d’Innate Pharma au 17 juillet 2019
25/07/2019
NOUVEAU NOMBRE D’ACTIONS ET DE DROITS DE VOTE D’INNATE PHARMA AU 17 JUILLET 2019 Marseille, le 25 juillet 2019, 7h00 CET Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l’ [...]
CEPI awards up to US$23.4 million to Valneva for late-stage development of a single-dose Chikungunya vaccine
25/07/2019
CEPI awards up to US$23.4 million to Valneva for late-stage development of a single-dose Chikungunya vaccine Oslo, Norway, and Saint-Herblain, France, July 25, 2019 —Valneva SE (“Valneva”), a biotech company developing [...]
CEPI octroie un financement à Valneva d’une valeur maximale de $23.4 millions pour le développement avancé d’un vaccin à injection unique contre le chikungunya
25/07/2019
CEPI octroie un financement à Valneva d’une valeur maximale de $23.4 millions pour le développement avancé d’un vaccin à injection unique contre le chikungunya Oslo, Norvège et Saint-Herblain, France, 25 juillet 2019 — [...]
Pixium Vision announces H1 2019 financial results and provides business update
25/07/2019
12-month data confirm and extend 6-month results in Prima System feasibility study Engaging with regulators to design development plan for Prima System in US Evaluating potential for parallel development in US and [...]

Pages